Overview

Safety and Efficacy Study of High Dose Colistin

Status:
Unknown status

Trial end date:
2016-10-01

Target enrollment:

Participant gender:

Summary

Colistin is a rapidly acting bactericidal antimicrobial agent that possesses a post antibiotic effect against MDRO Gram-negative bacteria, such as as Pseudomonas aeruginosa, Acinetobacterbaumannii, and Klebsiella pneumonia.

Phase:

Phase 4

Details

Lead Sponsor:

King Saud Medical City

Treatments:

Colistin